Despite good Q2 numbers Jubilant Life Sciences dips

Jubilant Life Sciences’ consolidated revenue for the quarter ended on September 2018 stood at Rs. 2,269 crore, up by 38 per cent YoY. This was led by stellar performance across all the segment, Pharmaceuticals division which account for 58 per cent of revenue recorded 55 per cent yoy growth. Also, Life Science Ingredients which account for 39 per cent of revenue grew by 20 per cent yoy.

Its EBITDA for the quarter was up by almost 38 per cent yoy to Rs. 478 crore. EBITDA margin for the quarter stood at 21 per cent. Net profit during the quarter surged almost 64 per cent yoy to Rs. 210 crore.

During Q2FY19, the company reduced its debt by Rs. 83 crore and net debt stood at Rs. 3,164 crore.

However, despite positive result, the stock of Jubilant Life Sciences was quite volatile after reporting this numbers and went down to touch an intra-day low of Rs. 644.10 per share, down by almost 4 per cent from its previous close.